Seaport Therapeutics, Inc. - Common Stock (NQ:SPTX)

Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

October 09, 2026

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Performance

52-Week Range 39.6% below 52-week high

17.15

14.8552W Low 28.3852W High

1 Week 10.0% below 1-week high

17.041W Low 19.051W High

Seaport Therapeutics, Inc. - Common Stock (SPTX) traded between $14.85 and $28.38 over the past 52 weeks and last traded at $17.15, 39.6% below its 52-week high. Over the past week it ranged between $17.04 and $19.05.

Past 12 Months

-1.3%

-30.6%

-14.7%

-13.6%

1W -$0.22

1M -$7.55

3M -$2.95

6M -$2.69

YTD -$2.69

1Y -$2.69

SPTX was -13.6% over the past year, -13.6% over six months, -13.6% year to date, -1.3% in the last week.

12 Months vs Market

SPTX

-13.6%

DIA

+12.4%

SPY

+17.4%

QQQ

+23.9%

IWM

+13.7%

Over the past 12 months SPTX returned -13.6% versus DIA (Dow) +12.4%, SPY (S&P 500) +17.4%, QQQ (Nasdaq 100) +23.9% and IWM (Russell 2000) +13.7%.

Volume & Liquidity

193.4K

314.4K

183.0K

264.1K

YTD

264.1K

SPTX's 3-month average daily volume is 183.0K.

More News

October 07, 2026

Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance

October 07, 2026

Seaport Therapeutics to Participate in September Investor Conferences

September 14, 2026

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

September 09, 2026

Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

September 09, 2026

Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference

August 31, 2026

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

August 03, 2026

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

June 09, 2026

Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

June 08, 2026

Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

June 08, 2026

Seaport Therapeutics to Participate in Two Upcoming Investor Conferences

June 01, 2026